(Q34131807)

English

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

object named as

Susan L Cohn

6

0 references

Katherine K Matthay

7

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

31 July 2017

author name string

Wendy B London

1

1 reference

Europe PubMed Central

31 July 2017

Christopher N Frantz

2

1 reference

Europe PubMed Central

31 July 2017

Laura A Campbell

3

1 reference

Europe PubMed Central

31 July 2017

Robert C Seeger

4

1 reference

Europe PubMed Central

31 July 2017

Babette A Brumback

5

1 reference

Europe PubMed Central

31 July 2017

Robert P Castleberry

8

1 reference

Europe PubMed Central

31 July 2017

Lisa Diller

9

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

26 July 2010

1 reference

Europe PubMed Central

31 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

31 July 2017

28

1 reference

Europe PubMed Central

31 July 2017

3808-3815

1 reference

Europe PubMed Central

31 July 2017

24

1 reference

Europe PubMed Central

31 July 2017

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Factors influencing survival in children with recurrent neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

28 October 2018

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

28 October 2018

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.27.5016

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34131807&oldid=1990379466"